Correlation Between Cellectis and ImmunoCellular Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cellectis and ImmunoCellular Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cellectis and ImmunoCellular Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cellectis SA and ImmunoCellular Therapeutics, you can compare the effects of market volatilities on Cellectis and ImmunoCellular Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cellectis with a short position of ImmunoCellular Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cellectis and ImmunoCellular Therapeutics.

Diversification Opportunities for Cellectis and ImmunoCellular Therapeutics

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Cellectis and ImmunoCellular is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Cellectis SA and ImmunoCellular Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ImmunoCellular Therapeutics and Cellectis is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cellectis SA are associated (or correlated) with ImmunoCellular Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ImmunoCellular Therapeutics has no effect on the direction of Cellectis i.e., Cellectis and ImmunoCellular Therapeutics go up and down completely randomly.

Pair Corralation between Cellectis and ImmunoCellular Therapeutics

If you would invest (100.00) in ImmunoCellular Therapeutics on November 29, 2024 and sell it today you would earn a total of  100.00  from holding ImmunoCellular Therapeutics or generate -100.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy0.0%
ValuesDaily Returns

Cellectis SA  vs.  ImmunoCellular Therapeutics

 Performance 
       Timeline  
Cellectis SA 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Cellectis SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's essential indicators remain nearly stable which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
ImmunoCellular Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days ImmunoCellular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, ImmunoCellular Therapeutics is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Cellectis and ImmunoCellular Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cellectis and ImmunoCellular Therapeutics

The main advantage of trading using opposite Cellectis and ImmunoCellular Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cellectis position performs unexpectedly, ImmunoCellular Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoCellular Therapeutics will offset losses from the drop in ImmunoCellular Therapeutics' long position.
The idea behind Cellectis SA and ImmunoCellular Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets